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validity of network meta-analysis; and (iv) the possibility of disagreement between 
direct evidence and indirect evidence. We illustrate the framework using a network 
meta-analysis of topical antibiotics without steroids for chronically discharging ears 
with underlying eardrum perforations.
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BAckground: In July 2013 the Department of Health referred terms of refer-
ence for value based assessment of health technologies to NICE. oBjective: We 
present the approach taken over the past 11 months to amending the Guide to 
Methods of Technology Appraisal to incorporate burden of illness and wider societal 
impact. Methods: Given the time frame available, NICE built on prior work under-
taken by the Department of Health (in the context of value based pricing) on the 
concepts of burden of illness and wider societal benefits by commissioning the NICE 
Decision Support Unit to review and critique this existing work. NICE reconvened the 
working party from the Guide to the Methods of Technology Appraisal review which 
took place in 2012, which included standing membership drawn from the stake-
holder communities such as patient and professional organisations, academia and 
pharmaceutical industry. The working party considered the prior work undertaken 
by the Department of Health and the Decision Support Unit’s critique for burden of 
illness and wider societal benefit, and provided advice on the incorporation of the 
2 new value elements into NICE’s current methods at 4 meetings. A consultation 
paper describing NICE’s proposals and draft of the amended sections of the methods 
guide was published in March 2014, and consultation ran for 12 weeks. It is antici-
pated that the final amendment of the methods guide will be considered by the 
NICE Board in advance of the ISPOR conference. results: Key points drawn from 
the discussion at the working party and consultation responses regarding burden 
of illness and wider societal impact, will be discussed. discussion: Considering 
NICE’s ‘position’ in the world of health technology assessment and appraisal, the 
conclusions from this latest amendment of the Guide to Methods of Technology 
Appraisal to incorporate value based assessment will be (highly) anticipated.
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oBjectives: To evaluate the cost-effectiveness (CE) of imaging-guided strategies 
for the diagnosis of significant coronary artery disease (CAD) in patients with inter-
mediate pre-test likelihood. Methods: Significant CAD was defined at invasive 
coronary angiography (ICA) as > 50% stenosis in the left main or > 70% stenosis in 
a major coronary vessel or 30-70% stenosis with fractional flow reserve ≤ 0.8.Nine 
diagnostic strategies were compared using a CE analysis. Strategies included the use 
of one single or two combined non-invasive imaging tests (CTCA as first line test 
and then stress ECHO, CMR, PET or SPECT) followed by ICA in the case of positivity 
of the single test or both non-invasive examinations in the case of combinations. 
ICERs were obtained using per-patient data collected throughout the EVINCI multi-
centre European study. Strategy costs were calculated using examination country-
specific reimbursements, while effectiveness was defined as the percentage of 
correct diagnosis. All costs were converted to Euro 2012 and adjusted using PPP. A 
propensity-score adjustment was used in the analysis and 95%CI were obtained 
with non-parametric bootstrap. results: Among the strategies analysed only three 
resulted cost-effective for the diagnosis of significant CAD. These included stress 
ECHO and CTCA as single non-invasive test, CTCA first then ECHO, CTCA first and 
then stress PET, all followed by ICA when required. Stress ECHO approach was the 
least costly but also the least effective, while CTCA alone [ICER: 2345 (2287-2400)] or 
in combination with PET [ICER: 5227(5161-5296)] had increasingly higher effective-
ness for a willingness to pay (WTP) exceeding 2,000 Euro and 5,000 Euro, respec-
tively. conclusions: Results from the health-economic analysis of the EVINCI 
study showed that stress ECHO guided diagnostic strategy could be cost-effective 
when the WTP is low. Strategies involving CTCA alone or as first line exam followed 
by stress PET could allow a more accurate diagnostic workflow for higher WTP.
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oBjectives: Clinical guideline recommendations are generally informed by pop-
ulation-based evidence. However, interventions that are (cost-)effective on average 
may not be (cost-)effective for many (even for most) patients meeting trial inclusion 
criteria. This study aims to investigate the value of risk-stratified recommendations 
for lung cancer screening among current or former smokers between the ages of 
55 and 74 years compared to a screen-all policy. Methods: Using data from the 
National Lung Cancer Screening Trial (NLST), we calculated the costs and QALYs 
for low-dose computed tomography (CT) versus chest radiography (X-ray) from 
empirically observed health states and 6 years life expectancy. Based on Kovalchik’s 
risk of lung cancer death prediction model, we stratified 53,454 NLST trial patients 
into quintiles. The expected value of individualized care (EVIC) was calculated to 
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oBjectives: To develop a set of criteria to critically appraise the strengths and 
weaknesses of health economic methods for the systematic valuation of interven-
tions for ultra-rare disorders (URDs). Methods: An international group of clinical 
and health economic experts met in conjunction with the Annual European ISPOR 
Congresses in Berlin/Germany and Dublin/Ireland, November 2012 and 2013, to 
deliberate and agree on a set of criteria to assess the potential of the various meth-
ods, which have been used or proposed to estimate the social value of medical 
interventions for URDs. results: The group identified a broad set of potential 
criteria, which may be grouped according to the following dimensions: theoreti-
cal foundations (normative premises, i.e., links to moral and economic theories, 
including - but not limited to – nonutilitarian consequentialist and deontological 
reasoning, definition and treatment of core concepts of economic thinking such 
as opportunity costs and efficiency), empirical underpinnings (social preferences 
related to attributes of the health condition or of the person afflicted with it), and 
pragmatic aspects (feasibility of implementation and potential for bias and misuse). 
For each of the dimensions, a set of criteria has been agreed upon, which in turn 
will need further scrutiny and justification. conclusions: Previously, a need had 
been identified for modifications or alternatives to the conventional logic of cost 
effectiveness applying benchmarks for the maximum allowable cost per quality-
adjusted life year (QALY). We propose a framework for the systematic assessment 
how well different evaluation approaches reflect prevalent social norms and value 
judgments. As a next step, the framework shall be applied on multi-criteria decision 
analysis methods and social cost value analysis, either using the person trade-off 
(PTO) or the relative social willingness-to-pay (RS-WTP) instrument.
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Rapid development of medical innovations in the face of rising health care costs have 
been calling for a more value-conscious adoption and diffusions of innovations. This 
conceptual paper departs from swift adoption of the da Vinci surgical robot in the 
Netherlands. It describes three challenges facing health care systems to evaluate 
promising, yet complex and often expensive medical innovations. Firstly, they are 
often adopted and diffused prior to their evidence-based superiority being proven. 
Secondly, formal evaluation frameworks are somehow detached from the dynamics 
of and incentives for adoption and diffusion of these innovations. Third, the real risks 
and benefits of these innovations are not easily amenable to an experimental inquiry. 
Unlike pharmaceuticals, whose impact is intrinsic to its biochemical components and 
thus can be subject to experiment, the value of complex surgical devices, imaging 
equipments, or targeted therapy interventions are inseparable from actual patterns 
of human practices and clinical pathways that utilize them. Multi-stakeholder (early) 
deliberation has often been proposed to better align value requirements with the 
adoption and diffusion processes. This article examines the importance of developing 
a shared value perspective on the implementation of complex innovations through 
early deliberation. Product developers, (potential) adopters (providers or patients), 
purchasers, and policy makers may engage in an upfront iterative deliberation on all 
the particularities and (pre)conditions that account for delivering value of a certain 
innovation during early adoption in a given care delivery setting. Such deliberation 
offers a cumulative learning as to how to reduce true-to-life uncertainties and risks 
‘along the way’, thereby serving for value ‘fulfillment’ in practice. Implication of such 
situated deliberative platforms for technology (outcome) assessment and for the role 
of authorities is discussed. A concrete framework for multi-stakeholder deliberation 
applied to the case of the da Vinci surgical robot in the Netherlands is also proposed.
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Systematic reviews that collate data about the relative effects of multiple inter-
ventions via network meta-analysis are highly informative for decision-making 
purposes. A network meta-analysis provides two types of findings for a specific 
outcome: the relative treatment effect for all pairwise comparisons, and a rank-
ing of the treatments. It is important to consider the confidence with which these 
two types of results can enable clinicians, policy makers and patients to make 
informed decisions. We propose an approach to determining confidence in the 
output of a network meta-analysis, based on methodology developed by the Grading 
of Recommendations Assessment, Development and Evaluation (GRADE) Working 
Group for pairwise meta-analyses. The suggested framework for evaluating a 
network meta-analysis acknowledges (i) the key role of indirect comparisons (ii) 
the contributions of each piece of direct evidence to the network meta-analysis 
estimates of effect size; (iii) the importance of the transitivity assumption to the 
